KRTX

Why Is Karuna Therapeutics (KRTX) Stock Moving Today?

By William White, InvestorPlace Writer
Karuna Therapeutics (KRTX) stock is on the move Monday after releasing positive results from a Phase 3 clinical trial for KarXT.

7 Momentum Stocks to Buy Now for Extraordinary Gains

By Alex Sirois, InvestorPlace Contributor
Momentum stocks aren't as risky as some say, and these winning stocks are strong examples for investors to consider.

Karuna Therapeutics (KRTX) Stock Soars 64% on Positive Clinical Data

By William White, InvestorPlace Writer
Karuna Therapeutics (KRTX) stock is rocketing higher on Monday thanks to results from a Phase 3 EMERGENT-2 trial to treat schizophrenia.

7 Risky Stocks to Buy Now for Growth and Exciting Returns

By Louis Navellier and the InvestorPlace Research Staff
It’s a frothy market, so why not have a bit of fun while the good times roll? These risky stocks to buy have great potential.

The Top Performing Sector in 2020 Will Be …

By InvestorPlace Research Staff
The future of healthcare will really start to take shape this year, and the next decade will bring advancements that we can only imagine in our wildest dreams.

The Price of Karuna Therapeutics Stock Is Too Tough to Swallow

By Josh Enomoto, InvestorPlace Contributor
In just a matter of a single day, KRTX stock skyrocketed to triple-digit gains. However, Karuna Therapeutics remains a risky pharma play when all is said and done.

What to Do with Karuna Stock After It Soared and Then Plunged

By Chris Lau, InvestorPlace Contributor
Almost immediately after Karuna Therapeutics (NASDAQ:KRTX) soared to $152, the company priced a public offering of its stock. So, after the cash raise torpedoed the…

Karuna Therapeutics News: KRTX Stock Skyrockets 415% on Positive Schizophrenia Trial

By William White, InvestorPlace Writer
Karuna Therapeutics (KRTX) news for Monday concerning a Phase 2 clinical trial of schizophrenia drug KarXT has KRTX stock soaring.